title: Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125.
authors.affiliation: Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 65 Brno, The Czech Republic.
authors.forename: Mirka
authors.initials: M
authors.lastname: Nekulova
authors.forename: Ladislav
authors.initials: L
authors.lastname: Pecen
authors.forename: Renata
authors.initials: R
authors.lastname: Kalabova
authors.forename: Marta
authors.initials: M
authors.lastname: Simickova
authors.forename: Ondrej
authors.initials: O
authors.lastname: Topolcan
authors.forename: Richard
authors.initials: R
authors.lastname: Pikner
authors.forename: Vladimir
authors.initials: V
authors.lastname: Vondracek
authors.forename: Dalibor
authors.initials: D
authors.lastname: Valik
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D012016:Reference Values
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D017239:Paclitaxel